• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Rituximab not beneficial long-term in Sjorgen’s Syndrome

byAimme Li, MDandKenan Celtik, MS
February 18, 2014
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. The results of this study suggest that rituximab (Rituxin) treatment is not associated with a significant improvement in symptoms or disease activity at 6 months for patients with primary Sjogren syndrome (pSS). 

2. There were transient improvements in fatigue symptoms at 6 weeks, but the benefits were no longer significant at 6 months. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Primary Sjogren’s Syndrome (pSS) is a chronic autoimmune condition mainly characterized by diminished salivary and lacrimal function.  The disease can often result in debilitating symptoms.  Given prior evidence of the pathophysiological role of B-cells in pSS, there has been interest in the possible therapeutic benefit of rituximab, a monoclonal antibody against B-cells often used in the treatment of other rheumatologic conditions. Two previous small randomized, control trials (RCTs) demonstrated the efficacy of rituximab in reducing fatigue and dryness symptoms after 6 months.  This larger placebo-control RCT aimed to evaluate the efficacy and adverse effects of rituximab in pSS.  The results of this study showed although there was some alleviation of symptoms at week 6, there was no significant improvement in symptoms or disease activity at 6 months in those patients receiving rituximab compared to the control group. In terms of safety, the rituximab group was associated with a higher rate of infusion-related reactions.  Limitations of this study include the low baseline disease activity of patients included. Overall, this study provides evidence that treatment with rituximab does not provide long-lasting disease control for patients with pSS.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: Effectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, double-blind, placebo-controlled trial

RELATED REPORTS

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

Single dose of rituximab for new-onset myasthenia gravis associated with reduced risk of disease manifestations – The RINOMAX Randomized Clinical Trial

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

In-Depth [randomized controlled trial]: The TEARS study (Tolerance and Efficacy of Rituximab in Primary Sjogren’s Syndrome) compared the symptoms of patients with primary Sjogren syndrome in patients randomly assigned to receive two doses of 1-gram rituximab (n=63) or placebo solvent (n=59) at week 0 and 2. The study included 122 patients who met the American-European Consensus Group criteria for pSS with onset in the last 10 years and other criteria for biologically active or systemic pSS. All patients received 100mg methylprednisolone intravenous plus 500mg acetaminophen orally before each infusion. Rituximab did not achieve the primary end-point of significantly improving at least two symptoms (≥30-mm decrease in ≥2 of 4 VAS [visual analogue scale] scores) at week 24. At week 6 and 16, there was a transient, clinically significant reduction in fatigue (p-value <0.001 and 0.012, respectively), but the benefit did not last through the 24 week study duration. The disease activity and treatment efficacy as assessed by investigator-physicians were significantly improved at only week 6 (p=0.011 and 0.001, respectively), but the ESSDAI score [European League Against Rheumatism Sjogren’s Syndrome Disease Activity Index], a validated clinical disease activity index for systemic primary Sjogren’s syndrome was not significantly improved at any point in the study.  There were no significant improvements in symptoms or disease activity at the end of the 24 week follow-up period.

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

 

Tags: RituxanrituximabSjorgen’s Syndrome
Previous Post

Intracranial carotid artery atherosclerosis independently linked to increased stroke risk

Next Post

H2 receptor antagonists associated with lower risk of bleeding and infections vs. PPIs

RelatedReports

#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma
StudyGraphics

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

October 19, 2022
Autologous hematopoietic stem cell transplantation associated with long-term remission in myasthenia gravis
Chronic Disease

Single dose of rituximab for new-onset myasthenia gravis associated with reduced risk of disease manifestations – The RINOMAX Randomized Clinical Trial

September 28, 2022
#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Oncology

Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics

February 22, 2022
Next Post
H2 receptor antagonists associated with lower risk of bleeding and infections vs. PPIs

H2 receptor antagonists associated with lower risk of bleeding and infections vs. PPIs

Wound surgical device found ineffective at infection control: ROSSINI Trial

Ambulatory surgery associated with low rates of postsurgical visits for infections

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Exhaled volatile organic compounds predict bronchopulmonary dysplasia in preterm infants
  • Wellness Check: Mental Health
  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options